These properties have drawn attention to their potential to treat metabolic disease, and the glucagon-like peptide-1 (GLP-1) drug class is now a well-established treatment for Type 2 diabetes (T2D) and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.